All In Biotech

Free tool

FAERS Monitor: Kengreal

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204958 or its brand name (Kengreal, Cangrelor). Reports on generic versions are filed under their own applications.

Reports

404

Serious

290

72% of reports

Hospitalization

83

Death reported

84

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use160
  • vascular stent thrombosis32
  • drug ineffective31
  • haemorrhage26
  • death22
  • no adverse event20
  • cardiac arrest18
  • inappropriate schedule of product administration18
  • cardiogenic shock15
  • gastrointestinal haemorrhage14
  • dyspnoea12
  • labelled drug-drug interaction medication error12
  • cerebral haemorrhage11
  • intentional product use issue11
  • haemorrhage intracranial10

Reports by year received

View as table
YearReports
20061
20072
20081
20111
20122
20138
20142
20157
201619
201729
201822
201946
202055
202118
202228
202340
202453
202548
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,755 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vascular stent thrombosisSignal32831.7594.825,326
labelled drug-drug interaction medication errorSignal1270.840.5756
cardiogenic shockSignal1554.533.1735
haemorrhage intracranialSignal1034.818.9296
cerebral haemorrhageSignal1116.08.9140
haemorrhageSignal2613.08.9276
cardiac arrestSignal1811.47.2160
off label useSignal1609.58.41,263
gastrointestinal haemorrhageSignal148.75.288
intentional product use issueSignal116.53.646
no adverse eventSignal205.73.774
inappropriate schedule of product administrationSignal185.23.357
death221.30.92
drug ineffective311.20.91
dyspnoea121.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.